End‐stage renal disease · patients with hypertension
RAS inhibitors showed no clear difference in end stage renal failure compared with CCBs (low certainty).
1 finding from 1 review
All‐cause death · patients with hypertension
RAS inhibitors showed no clear difference in all‐cause death compared with thiazides (moderate certainty).
1 finding from 1 review
Cardiovascular events · patients with hypertension
RAS inhibitors showed no clear difference in total cardiovascular events compared with thiazides (moderate certainty).
1 finding from 1 review
Death or hospitalization for heart failure · patients with hypertension
RAS inhibitors probably leads to higher death or hospitalization for heart failure compared with thiazides (moderate certainty).
1 finding from 1 review
Total mortality
Beta‐blockers showed no clear difference in total mortality compared with renin‐angiotensin system inhibitors (moderate certainty).
1 finding from 1 review
Total cardiovascular disease
Beta‐blockers showed no clear difference in total cardiovascular disease compared with renin‐angiotensin system inhibitors (low certainty).
1 finding from 1 review
Stroke
Beta‐blockers probably leads to higher total stroke compared with renin‐angiotensin system inhibitors (moderate certainty).
1 finding from 1 review
Total coronary heart disease
Beta‐blockers showed no clear difference in total coronary heart disease compared with renin‐angiotensin system inhibitors (low certainty).
1 finding from 1 review
Withdrawals due to adverse events
Beta‐blockers probably leads to higher withdrawal due to adverse effect compared with renin‐angiotensin system inhibitors (moderate certainty).
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 150 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 300 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Systolic BP ‐ Aliskiren 600 mg vs. placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 150 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension
The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).
1 finding from 1 review